Early AI/ML application in the pharmacovigilance workflow

Discover how technology can be used to leverage PSPs in order to minimize missed adverse events and improve patient outcomes, plus learn the:

Benefits of combining human expertise with AI/Machine Learning
Impact on operational efficiency
Qualitative impact
Ongoing challenges

Download the Whitepaper

Your company email address

Please select your industry: (max 1)
Yes, I would like to be contacted by an IQVIA expert

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow IQVIA to store and process the information submitted to provide you the content requested. They are subject to IQVIA Terms and Conditions.

Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

In this webinar, we will present key insights from preliminary findings by the TUFTS Center for the Study of Drug Development, exploring how a comprehensive model that brings CDMO and CRO services under one roof can significantly impact the expected Net Present Value (eNPV) of drug development programs. We will demonstrate how streamlined services across drug substance, drug product, and clinical research can enhance efficiency, reduce timelines, and ultimately deliver high-quality therapies to patients faster. Key takeaways include:

Early AI/ML application in the pharmacovigilance workflow

Download the Whitepaper

Opt In?

Explore similar content

Safety & Regulatory Compliance Predictions For 2025

Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

Getting The Most Out Of Your Lab Space